Physician profile
Danilo N Ablan
NPI 1972608032
$9,915.16
in general payments reported to CMS, 2019-2025
18 companies · $2,155 in 2025
The $2,155 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $835 · 2021: $1,020 · 2022: $1,667 · 2023: $1,843 · 2024: $1,523 · 2025: $2,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,420 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,419.93 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $3,353.99 | 2019-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals Lp | $2,212.81 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,698.54 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $755.23 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.90 | 2019-2025 | Stiolto Respimat, Ofev |
| Regeneron Healthcare Solutions, INC. | $421.71 | 2019-2024 | Dupixent |
| Philips North America LLC | $247.09 | 2021-2025 | (8874) Incourage, Encore |
| Verona Pharma, INC. | $139.98 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $116.80 | 2021 | |
| Allergan, INC. | $109.90 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.86 | 2022 | |
| Abbvie INC. | $77.59 | 2021-2023 | Avycaz |
| Lilly USA, LLC | $45.62 | 2025 | Zepbound |
| Fisher & Paykel Healthcare INC | $24.71 | 2023 | Fisher & Paykel Healthcare |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.55 | 2019 | |
| Caris Mpi, INC. | $23.48 | 2025 | Mi Cancer Seek |
| Tactile Systems Technology INC | $14.45 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danilo Ablan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.